Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

LAB282, the £13m drug discovery partnership for Oxford University, has made its first wave of awards, backing projects targeting cardiovascular and infectious diseases.

Launched last year as a partnership between the University, Evotec and Oxford Sciences Innovation, LAB282 aids the rapid translation of research outputs into new drug discovery and development programmes. It draws on expertise provided by Evotec and combines that with pre-clinical proof-of-concept grant funding to accelerate projects into a position where they can be commercialised and scaled up efficiently and effectively.

Read more (Oxford University Innovation Website) 

Similar stories

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Two major BHF awards to Neil Herring pave the way to new treatments for heart attack patients

CRE Research

Associate Professor Neil Herring has been awarded a Senior Clinical Research Fellowship and a Project grant from the British Heart Foundation to further critical research into the mechanisms behind heart attacks and heart failure and potential drugs to combat them. Given the 50% reduction in research investment this year from the BHF due to the impact of COVID-19, Prof Herring is to be congratulated on these awards.